Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network

Articles by Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel concludes with a candid discussion about the most urgent changes that could improve cancer care today.
View More
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the importance of introducing palliative care discussions earlier in the treatment journey.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the overlooked burden of financial toxicity and proactively raising the topic with patients.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores how clinicians can build trust with patients from diverse backgrounds and ensure care is patient-centered.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores how clinicians can introduce clinical trial options while maintaining trust in the face of uncertainty.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the emotional weight of a cancer diagnosis and the importance of empathetic communication.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | February 19, 2025
Newly presented research on the CALGB-90203 (PUNCH) and NRG/RTOG-0521 trials are discussed.
Christopher Wallis, MD, PhD, FRCSCCRPC | October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
Christopher Wallis, MD, PhD, FRCSCAdvanced Renal Cell Carcinoma | September 23, 2024
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Christopher Wallis, MD, PhD, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 23, 2024
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Alicia Morgans, MD, MPHCRPC | June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Soumyajit Roy, MDCRPC | June 6, 2024
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Christopher Wallis, MD, PhD, FRCSCnmCRPC | June 3, 2024
Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.